SynthesisPloS one2025
The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Development and validation of an early prediction model for bee-sting-induced acute kidney injury using machine learning.Renal failure · 2026Article
- Boeravinone A Alleviates Oxidative Stress and Inflammation in LPS-Induced Acute Kidney Injury by Targeting PGK1.Antioxidants (Basel, Switzerland) · 2026Article
- Creatinine's hidden compartments: why cystatin C "Gets there first".Pediatric nephrology (Berlin, Germany) · 2026Article
- Article
- Early Renal Microcirculatory Perfusion Patterns in Sepsis: Associations with SA-AKI Trajectories in the Emergency Department.Diagnostics (Basel, Switzerland) · 2026Article
- Serum renin levels refine acute kidney injury prediction in critically ill children.Pediatric nephrology (Berlin, Germany) · 2026Observational
- The Impact of Nurse Staffing and Education on 30-Day Mortality Among Patients Hospitalized for Acute Kidney Injury.Research in nursing & health · 2026Article
- Risk of Rhabdomyolysis and Kidney Injury after Intensive Exercise. Potential of Novel Biomarkers of Kidney Injury: A Narrative Review.Journal of human kinetics · 2026Review
- A Review of the Clinical Utility of Tubule-Specific Biomarkers in Sickle Cell Nephropathy.BioMed research international · 2026Review
- Renal Alterations Secondary to Visceral Leishmaniasis: A Scoping Review.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Article
- Evaluation of a Novel Biomarker Panel for Acute Kidney Injury Following Endovascular Aortic Repair.International journal of molecular sciences · 2025Article
- The Utility of Urine Microscopy Score for Early Detection and Prediction of Acute Kidney Injury in At-Risk Patients.Kidney360 · 2025Article
- Yuanhuacine modulates lipopolysaccharide-induced interleukin-6 through regulation of the JAK1/STAT3 pathway and prevents tubular damage in acute kidney injury.Experimental and therapeutic medicine · 2025Article
- Histopathology of Diabetic Nephropathy: Beyond Glomerular Basement Membrane Thickening.Cureus · 2025Review
- Review
- Correction: The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Article
- Influence of the type of volatile anesthetic on the development of acute kidney injury after endovascular repair of aortic aneurysm: a randomized controlled trial (DESEVAR study).Frontiers in pharmacology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management. Database searches yielded 17 relevant studies which were critically appraised. Key themes were biomarker efficacy in predicting AKI risk and severity before functional changes; potential to improve clinical management through earlier diagnosis, prognostic enrichment, and guiding interventions; emerging roles as therapeutic targets and prognostic tools; and ongoing challenges requiring further validation. Overall, novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cell cycle arrest markers ([TIMP-2] •[IGFBP7]) demonstrate capability for very early AKI prediction and accurate risk stratification. Their incorporation has potential to facilitate timely targeted interventions and personalized management. However, factors influencing biomarker performance, optimal cutoffs, cost-effectiveness, and impact on patient outcomes require robust validation across diverse settings before widespread implementation. Addressing these limitations through ongoing research can help translate novel biomarkers into improved detection, prognosis, and management of AKI in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.